.png "The CEO of BioMarin Pharmaceutical is Exercising Options")
Yesterday it was reported that the CEO of BioMarin Pharmaceutical (BMRN), Jean Jacques Bienaime, exercised options to buy 1,000 BMRN shares at $21.51 a share, for a total transaction value of $21.51K.
Following Jean Jacques Bienaime’s last BMRN Buy transaction on November 26, 2019, the stock climbed by 5.5%.
See today’s analyst top recommended stocks >>
Based on BioMarin Pharmaceutical’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $455 million and quarterly net profit of $55.04 million. In comparison, last year the company earned revenue of $353 million and had a GAAP net loss of $3.65 million. The company has a one-year high of $100.13 and a one-year low of $62.88.
12 different firms, including Barclays and Merrill Lynch, currently also have a Buy rating on the stock.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its products include Aldurazyme, Brineura, Kuvan, Naglazyme, Palynziq and Vimizim.
Read More on BMRN:
